Arrow sells implantable drug infusion unit
This article was originally published in Clinica
Executive Summary
Arrow International is to sell its implantable drug infusion business after deciding that the investment needed to make the business a "significant contributor to future revenues" is not viable compared with other opportunities. Instead, the company will focus on other products in the critical care and cardiac assist businesses, notably the LionHeart and the CorAide.